Recently, H19 has been reported to promote EMT in CRC via a novel ceRNA mechanism, suggesting that upregulated H19 is a biomarker of CRC metastasis and, more importantly, could be a promising therapeutic target for CRC treatment. This evidence concerns the gene H19 and colorectal carcinoma.